Immunotherapy for cancer is a rapidly developing treatment that modifies the immune
system and enhances the antitumor immune response. B7-H3 (CD276), a member of the B7 …

Recent advances in cancer immunotherapy using monoclonal antibodies have dramatically
revolutionized the therapeutic strategy against advanced malignancies, inspiring the …

Administration of bispecific antibodies (biAbs) in tumor therapy is limited by their short half-
life and off-target toxicity. Optimized strategies or targets are needed to overcome these …

Twenty-five years ago, we reported that agonist anti-CD137 monoclonal antibodies
eradicated transplanted mouse tumors because of enhanced CD8+ T-cell antitumor …

Human mesenchymal stem cells (hMSCs)-derived extracellular vesicles (EVs) have been
known to possess the features of the origin cell with nano size and have shown therapeutic …

The B7/CD28 families of immune checkpoints play vital roles in negatively or positively
regulating immune cells in homeostasis and various diseases. Recent basic and clinical …

Abstract B7 homolog 3 (B7-H3, also called CD276) is a checkpoint of B7 family that is
aberrantly and consistently expressed in several human cancers, and its overexpression …

Simple Summary CD137 is an interesting immuno-oncology target. The recent advances in
CD137 targeting technologies to mitigate toxicity while maintaining potency have made this …

Abstract The CD47/PD‐L1 antibodies combination exhibits durable antitumor immunity but
also elicits excessive immune‐related adverse events (IRAEs) caused by the on‐target off …

Following the clinical success of cancer immunotherapies such as immune checkpoint
inhibitors blocking B7/CTLA-4 or PD-1/PD-L1 signaling and ongoing numerous combination …